Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 30, Issue 6, Pages 790-797Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-010-9458-6
Keywords
Neonatal Fc receptor; FcRn; Fcgrt; beta(2) microglobulin; therapeutic antibodies; albumin
Categories
Funding
- NIH [R01 DK56597, T31 DK07449]
Ask authors/readers for more resources
Introduction Knowledge that antibodies of the IgG isotype have remarkably extended persistence in circulation and are able to pass through cell barriers has substantial implications. While it is well established that so-called neonatal Fe receptor, FcRn, acts throughout life to confer these unusual properties, its ramifications on clinical medicine and therapeutic uses are not broadly appreciated. Scope Here we discuss basic principles and gaps in understanding of FcRn, including its management of IgG antibodies and along with albumin, its impact on use and design of antibody-based therapeutics, and its genetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available